Abstract:Background: Colorectal cancer (CRC) cases with advanced or distal metastases experience a survival rate of less than 20%, with the lack of spectral therapeutic targets and prognostic markers posing a significant challenge for CRC treatment. SLC4A4 may be a CRC-targeted therapy for which there is currently inadequate evidence. background: Colorectal cancer (CRC) cases with advanced or distal metastases experience a survival rate of less than 20%, with the lack of spectral therapeutic targets and prognostic markers posing a significant challenge for CRC treatment. SLC4A4 may be a CRC-targeted therapy for which there is currently inadequate evidence. Aim: In this report, we performed a comprehensive analysis of data on colorectal cancer (CRC) to elucidate the association among Solute Carrier Family 4 Member 4 (SLC4A4) and the abundance of immunological features and immune cell infiltration in CRC and to explore the impact of SLC4A4 on the CRC tumor microenvironment. objective: To deeply and systematically reveal the characteristics of the tumor microenvironment created by SLC4A4. Objective: The objective of this study was to systematically reveal the characteristics of the tumor microenvironment created by SLC4A4. method: We downloaded RNA sequencing files (TCGA-COADREAD), clinical data for Colon Cancer (COAD) and Rectal Cancer (READ) from the Cancer Genome Atlas. We evaluated the spearman correlation of SLC4A4 with immune features, Tracking Tumor Immunophenotype (TIP) score, and immune checkpoint gene expression. SLC4A4/immunity-related differentially expressed genes (DEGs) were identified in SLC4A4 expression groups and immune groups, and an assessment system for predicting CRC prognosis was constructed based on univariate COX and multivariate COX analyses. Based on the prognostic factors in CRC, we also constructed a nomogram to assess the survival risk status of CRC. Besides, we evaluated the potential association of SLC4A4 to immunotherapy. Methods: We downloaded RNA sequencing files from the Cancer Genome Atlas (TCGA- COADREAD). The correlations of SLC4A4 with immune-related characteristics were analyzed. A Limma package was applied for selecting SLC4A4/immunity-related differentially expressed genes (DEGs). An assessment system for predicting CRC prognosis was constructed based on univariate COX and multivariate COX analyses. A nomogram was also designed to assess the survival risk status of CRC. Besides, we evaluated the potential association of SLC4A4 to immunotherapy through TIDE analysis. result: We found that SLC4A4 expression trended positively with immune checkpoint [removed]PD-L1, CTLA4) and promoted infiltration of 27 immune cells. SLC4A4 promoted the infiltration of CD8 T cells, Dendritic cells, Macrophage, NK cells, and Th1 cells in CRC, shaping the inflammatory tumor microenvironment. Up-regulation of SLC4A4 expression might promote drug response to Anti-FGFR3_therapy, Anti-PPARG_therapy, Nivolumab, Ipilimumab in CRC patients, and down-regulation of SLC4A4 expression might promote drug response to Anti-EGFR_therapy, Aflibercept drug response. Based on the SLC4A4/immunization-related DEGs, we constructed RiskScore to assess the prognosis of CRC, which showed excellent predictive effect and robustness. RiskScore showed a trend of negative correlation with SLC4A4, which was consistent with the trend of the effect of SLC4A4 on CRC survival. Besides, RiskScore could also be useful for predicting patient prognosis. Finally, we constructed a nomogram for predicting CRC survival based on metrics with independent prognostic value (Age, M stage, Stage, RiskScore), which showed potential clinical value. Results: We found that SLC4A4 expression was positively correlated with immune checkpoint expression (PD-L1). SLC4A4 promoted the infiltration of CD8 T cells, dendritic cells, macrophages, NK cells, and Th1 cells in CRC, shaping the inflammatory tumor microenvironment. Up-regulated SLC4A4 might improve drug response to anti- FGFR3 therapy, anti-PPARG therapy, nivolumab, and ipilimumab in CRC patients, and down-regulated SLC4A4 might promote drug response to anti-EGFR therapy and Aflibercept drug response. The constructed RiskScore model showed excellent predictive effect and robustness. RiskScore presented a trend of negative correlation with SLC4A4, which was consistent with the trend of the effect of SLC4A4 on CRC survival. TIDE analysis further disclosed that high-risk groups with high levels of SLC4A4 were possible for immune escape. Finally, the constructed nomogram also showed potential clinical value. Conclusion: Overall, upregulation of SLC4A4 expression promoted an inflammatory tumor microenvironment in CRC, and RiskScore predicted therapeutic expectancy. SLC4A4 could be a potentially clinically valuable target for CRC therapy.

Transcription network of SLC7A11 (xCT) in colon cancer provides clinical targets for metabolic regulation and cell proliferation

Gene expression analyses identify a relationship between stanniocalcin 2 and the malignant behavior of colorectal cancer.

Delineating the Underlying Molecular Mechanisms and Key Genes Involved in Metastasis of Colorectal Cancer Via Bioinformatics Analysis

SLC7A11/xCT in Cancer: Biological Functions and Therapeutic Implications.

Comprehensive Analyses of Solute Carrier Family Members Identify SLC12A2 As a Novel Therapy Target for Colorectal Cancer

SLC12A8 upregulation promotes colorectal cancer progression and chemoresistance

Identification and Validation of SLC9A2 as A Potential Tumor Suppressor in Colorectal Cancer: Integrating Bioinformatics Analysis with Experimental Confirmation

Xct (Slc7a11)-Mediated Metabolic Reprogramming Promotes Non-Small Cell Lung Cancer Progression

SLC11A1 associated with tumor microenvironment is a potential biomarker of prognosis and immunotherapy efficacy for colorectal cancer

SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA

Integrated Analysis of DNA Repair Genes Identifies SLC6A1 as a New Marker for the Clinical Outcome of Patients with Colorectal Cancer

Metabolic Heterogeneity of Tumor Cells and its Impact on Colon Cancer Metastasis: Insights from Single-Cell and Bulk Transcriptome Analyses

Identification of Key Genes and Pathways Involved in Circulating Tumor Cells in Colorectal Cancer

Up-regulated SLC25A39 promotes cell growth and metastasis via regulating ROS production in colorectal cancer

Development of a prognostic model for NSCLC based on differential genes in tumour stem cells

Abstract LB370: Exploring SLC35B family genes in colorectal carcinoma: Bioinformatics and functional insights into prognosis and therapy

Xct Contributes to Colorectal Cancer Tumorigenesis Through Upregulation of the MELK Oncogene and Activation of the AKT/mTOR Cascade.

SLC14A1 and TGF-β signaling: a feedback loop driving EMT and colorectal cancer metachronous liver metastasis

Pathway analysis of genome-wide association study and transcriptome data highlights new biological pathways in colorectal cancer

SLC25A19 drives colorectal cancer progression by regulating p53

SLC4A4 Moulds the Inflammatory Tumor Microenvironment and Predicts Therapeutic Expectations in Colorectal Cancer